- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc stock price live, this page displays NASDAQ RXRX stock exchange data. View the RXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Recursion Pharmaceuticals Inc real time stock price chart below.
What Is the Recursion Pharmaceuticals Inc Stock Price Today?
The Recursion Pharmaceuticals Inc stock price today is 3.61.
What Is the Stock Symbol for Recursion Pharmaceuticals Inc?
The stock symbol for Recursion Pharmaceuticals Inc is "RXRX."
What Stock Exchange Does Recursion Pharmaceuticals Inc Trade On?
Recursion Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Recursion Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Recursion Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXRX quote. (ISIN: US75629V1044)
What Is the Recursion Pharmaceuticals Inc Stock Price Today?
The Recursion Pharmaceuticals Inc stock price today is 3.61.
What Is the Stock Symbol for Recursion Pharmaceuticals Inc?
The stock symbol for Recursion Pharmaceuticals Inc is "RXRX."
What Stock Exchange Does Recursion Pharmaceuticals Inc Trade On?
Recursion Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Recursion Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Recursion Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXRX quote. (ISIN: US75629V1044)
3.61
-0.16(-4.25%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.59
3.72
52 wk Range
2.98
7.89
RXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.593.72
52 wk Range
2.987.89
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RXRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.71
Upside
+85.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Recursion Pharmaceuticals Inc Company Profile
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Recursion beat Q4 2025 forecasts with EPS of -$0.21 vs. -$0.30 expected; revenue hit $35.54M, exceeding estimates by 45%
- Operating expenses slashed 35% year-over-year; cash runway extended to early 2028 through financial discipline
- Stock surged 8.5% to $3.83 in pre-market trading following the earnings beat and strong revenue performance
- Company maintains Q1 EPS guidance at -$0.29; focuses on operational efficiency and strategic partnerships for growth
- CEO Gibson emphasized commitment to financial sustainability despite continued negative EPS and revenue variability from milestone payments
Last Updated: 02/25/2026, 10:30 PM
Read Full TranscriptCompare RXRX to Peers and Sector
Metrics to compare | RXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −5.8x | −0.6x | |
PEG Ratio | −0.21 | −0.10 | 0.00 | |
Price/Book | 1.7x | 3.0x | 2.6x | |
Price / LTM Sales | 25.8x | 19.7x | 3.3x | |
Upside (Analyst Target) | 59.2% | 74.1% | 44.5% | |
Fair Value Upside | Unlock | −12.7% | 5.2% | Unlock |
Analyst Ratings
3 Buy
5 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.71
(+85.99% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
-0.21 / -0.30
Revenue / Forecast
35.54M / 24.51M
People Also Watch
FAQ
What Is the Recursion Pharmaceuticals (RXRX) Stock Price Today?
The Recursion Pharmaceuticals stock price today is 3.61 USD.
What Stock Exchange Does Recursion Pharmaceuticals Trade On?
Recursion Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Recursion Pharmaceuticals?
The stock symbol for Recursion Pharmaceuticals is "RXRX."
What Is the Recursion Pharmaceuticals Market Cap?
As of today, Recursion Pharmaceuticals market cap is 1.91B USD.
What Is Recursion Pharmaceuticals's Earnings Per Share (TTM)?
The Recursion Pharmaceuticals EPS (TTM) is -1.44.
When Is the Next Recursion Pharmaceuticals Earnings Date?
Recursion Pharmaceuticals will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is RXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Recursion Pharmaceuticals Stock Split?
Recursion Pharmaceuticals has split 0 times.
How Many Employees Does Recursion Pharmaceuticals Have?
Recursion Pharmaceuticals has 800 employees.
What is the current trading status of Recursion Pharmaceuticals (RXRX)?
As of Feb 27, 2026, Recursion Pharmaceuticals (RXRX) is trading at a price of 3.61 USD, with a previous close of 3.77 USD. The stock has fluctuated within a day range of 3.59 USD to 3.72 USD, while its 52-week range spans from 2.98 USD to 7.89 USD.
What Is Recursion Pharmaceuticals (RXRX) Price Target According to Analysts?
The average 12-month price target for Recursion Pharmaceuticals is 6.71 USD, with a high estimate of 11 USD and a low estimate of 3 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +85.99% Upside potential.
What Is the RXRX Premarket Price?
RXRX's last pre-market stock price is 3.64 USD. The pre-market share volume is 393,880.00, and the stock has decreased by -0.13, or -3.44%.
What Is the RXRX After Hours Price?
RXRX's last after hours stock price is 3.72 USD, the stock has decreased by -0.05, or -1.33%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.